Bio News
Swiss pharmaceutical company Roche said its Lunsumio combination therapy met the primary endpoint in a phase 3 follicular lymphoma trial.
The Lunsumio plus lenalidomide combination significantly improved progression-free survival compared with the rituximab plus lenalidomide combination.
Based on the results, Roche plans to convert the existing accelerated approval to full approval and pursue entry into the second-line treatment setting.
BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
